Chemical detection company MyDx Inc (OTC:MYDX) disclosed on Thursday the appointment of Jessica Peatross as its chief medical officer.
In the company's medical department, Dr Peatross will lead the clinical research initiatives, support formulation services to MyDx360 Customers, as well as offer doctor consultation for its customers through the MyDx App, including the possibility of writing medical cannabis prescriptions in all legal states.
Currently, Dr Peatross is a western trained, board certified medical doctor, a Gerson Therapy practitioner, a consultant in San Diego's premiere Nourish Medical Center as well as owns and operates an organically formulated nutraceutical line of products tailored to treating various chronic symptoms and illnesses.
Previously, Dr Peatross worked as a traditional doctor supporting patients in a level 1 trauma centre for six years as well as practised functional medicine with Optimal Health and Wellness and Whitiker Wellness.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA